| 6.47 0.11 (1.73%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.15 | 1-year : | 8.84 |
| Resists | First : | 6.98 | Second : | 7.57 |
| Pivot price | 6.42 |
|||
| Supports | First : | 6.03 | Second : | 5.01 |
| MAs | MA(5) : | 6.47  |
MA(20) : | 6.59 |
| MA(100) : | 8.46 |
MA(250) : | 9.04 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 39.7 |
D(3) : | 38.4 |
| RSI | RSI(14): 43.2 |
|||
| 52-week | High : | 37.5 | Low : | 3.8 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LYRA ] has closed below upper band by 40.1%. Bollinger Bands are 94% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 50 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.61 - 6.65 | 6.65 - 6.68 |
| Low: | 6.27 - 6.31 | 6.31 - 6.34 |
| Close: | 6.42 - 6.47 | 6.47 - 6.52 |
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Sat, 27 Sep 2025
What analysts say about Lyra Therapeutics Inc stock - Trading Volume Surges & Free Strong Return On Assets - Early Times
Thu, 11 Sep 2025
Lyra Therapeutics Receives Nasdaq Deficiency Letter - MSN
Fri, 22 Aug 2025
Lyra Therapeutics receives Nasdaq notice for non-compliance with equity requirement - Investing.com
Tue, 12 Aug 2025
Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Tue, 12 Aug 2025
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates - Nasdaq
Mon, 14 Jul 2025
Lyra Therapeutics CEO Palasis sells $13944 in stock - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 1.12e+006 (%) |
| Held by Institutions | 0.6 (%) |
| Shares Short | 46 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.534e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 605.4 % |
| Return on Equity (ttm) | -30.4 % |
| Qtrly Rev. Growth | 770000 % |
| Gross Profit (p.s.) | -408.24 |
| Sales Per Share | -1401.53 |
| EBITDA (p.s.) | -1.26353e+008 |
| Qtrly Earnings Growth | -29 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -43 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 1.09 |
| Dividend | 0 |
| Forward Dividend | 45600 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|